{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:41:42Z","timestamp":1792237302282,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":672,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1124\/dmd.122.001018","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:54:47Z","timestamp":1669769687000},"page":"293-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A in vitro"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8053-6889","authenticated-orcid":false,"given":"Marie-No\u00eblle","family":"Paludetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-4143","authenticated-orcid":false,"given":"Mika","family":"Kurkela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1972-7368","authenticated-orcid":false,"given":"Helin\u00e4","family":"Kahma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-2788","authenticated-orcid":false,"given":"Janne T.","family":"Backman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-2189","authenticated-orcid":false,"given":"Mikko","family":"Niemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-8265","authenticated-orcid":false,"given":"Anne M.","family":"Filppula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.122.001018_bib1","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/j.1552-4604.1994.tb01986.x","article-title":"Hematologic disposition of hydroxychloroquine enantiomers","volume":"34","author":"Brocks","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001018_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4258","article-title":"Development of a novel ion-pairing HPLC-FL method for the separation and quantification of hydroxychloroquine and its metabolites in whole blood","volume":"32","author":"Charlier","year":"2018","journal-title":"Biomed Chromatogr"},{"key":"10.1124\/dmd.122.001018_bib3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jchromb.2017.11.026","article-title":"Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS\/MS: An application for pharmacokinetic studies","volume":"1072","author":"Chhonker","year":"2018","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.122.001018_bib4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/jpet.117.245639","article-title":"Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation","volume":"365","author":"Collins","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.001018_bib5","series-title":"Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis","first-page":"270","article-title":"Modes of Reversible Inhibition","author":"Copeland","year":"2000"},{"key":"10.1124\/dmd.122.001018_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2125.1995.tb05768.x","article-title":"Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects","volume":"40","author":"Ducharme","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001018_bib7","unstructured":"FDA (2020) Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and (Last accessed Oct 26, 2022)."},{"key":"10.1124\/dmd.122.001018_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12886-015-0008-0","article-title":"Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy)","volume":"15","author":"Grassmann","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"10.1124\/dmd.122.001018_bib9","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19","volume":"383","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.122.001018_bib10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1055\/a-1325-0248","article-title":"Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients","volume":"71","author":"Idkaidek","year":"2021","journal-title":"Drug Res (Stuttg)"},{"key":"10.1124\/dmd.122.001018_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105810","article-title":"An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivity","volume":"162","author":"Kahma","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.122.001018_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/138920007780866807","article-title":"Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions","volume":"8","author":"Kalgutkar","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.122.001018_bib13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/BF02976712","article-title":"Cytochrome P450 2C8 and CYP3A4\/5 are involved in chloroquine metabolism in human liver microsomes","volume":"26","author":"Kim","year":"2003","journal-title":"Arch Pharm Res"},{"key":"10.1124\/dmd.122.001018_bib14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/art.39402","article-title":"Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus","volume":"68","author":"Lee","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1124\/dmd.122.001018_bib15","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00228-020-02928-7","article-title":"The parent drugs chloroquine and hydroxychloroquine do not inhibit human CYP3A activity in vitro","volume":"76","author":"Li","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001018_bib16","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1128\/AAC.00339-08","article-title":"Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax","volume":"53","author":"Lim","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.001018_bib17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1124\/jpet.121.000619","article-title":"Cationic Compounds with SARS-CoV-2 Antiviral Activity and Their Interaction with Organic Cation Transporter\/Multidrug and Toxin Extruder Secretory Transporters","volume":"379","author":"Martinez-Guerrero","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"issue":"1A","key":"10.1124\/dmd.122.001018_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","article-title":"Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate","volume":"75","author":"McChesney","year":"1983","journal-title":"Am J Med"},{"key":"10.1124\/dmd.122.001018_bib19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF00315548","article-title":"Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites","volume":"44","author":"McLachlan","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001018_bib20","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00280-019-03919-x","article-title":"A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors","volume":"84","author":"Mehnert","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.122.001018_bib21","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/art.10307","article-title":"Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis","volume":"46","author":"Munster","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1124\/dmd.122.001018_bib22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for Covid-19\u2014Interim WHO Solidarity Trial Results","volume":"384","author":"Pan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.122.001018_bib23","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1080\/00498250701620726","article-title":"In vitro\u2013in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations","volume":"37","author":"Pelkonen","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.122.001018_bib24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40261-018-0656-y","article-title":"Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review","volume":"38","author":"Plantone","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1124\/dmd.122.001018_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/00498250310001646353","article-title":"Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors","volume":"34","author":"Proctor","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.122.001018_bib26","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1124\/dmd.31.6.748","article-title":"In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation","volume":"31","author":"Projean","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001018_bib27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"Rainsford","year":"2015","journal-title":"Inflammopharmacology"},{"key":"10.1124\/dmd.122.001018_bib28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1124\/dmd.122.001018_bib29","article-title":"Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment","author":"Shimizu","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1124\/dmd.122.001018_bib30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.7326\/M20-4207","article-title":"Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial","volume":"173","author":"Skipper","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1124\/dmd.122.001018_bib31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2125.2000.00197.x","article-title":"Influence of hydroxychloroquine on the bioavailability of oral metoprolol","volume":"49","author":"Somer","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001018_bib32","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.2217\/pgs-2017-0077","article-title":"SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria","volume":"18","author":"Sortica","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1124\/dmd.122.001018_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3390\/pharmaceutics13010081","article-title":"Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters","volume":"13","author":"Telbisz","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1124\/dmd.122.001018_bib34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/psp4.12110","article-title":"Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?","volume":"5","author":"Templeton","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.122.001018_bib35","first-page":"145","article-title":"Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine","volume":"44","author":"Tett","year":"1993","journal-title":"Agents Actions Suppl"},{"key":"10.1124\/dmd.122.001018_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0378-4347(00)82024-1","article-title":"High-performance liquid chromatographic assay for hydroxychloroquine and metabolites in blood and plasma, using a stationary phase of poly(styrene divinylbenzene) and a mobile phase at pH 11, with fluorimetric detection","volume":"344","author":"Tett","year":"1985","journal-title":"J Chromatogr A"},{"key":"10.1124\/dmd.122.001018_bib37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2125.1988.tb05281.x","article-title":"A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers","volume":"26","author":"Tett","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001018_bib38","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","article-title":"Bioavailability of hydroxychloroquine tablets in healthy volunteers","volume":"27","author":"Tett","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001018_bib39","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s13318-020-00648-y","article-title":"Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization","volume":"45","author":"Th\u00e9mans","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.122.001018_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijcard.2021.04.062","article-title":"Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial","volume":"337","author":"Ulander","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1124\/dmd.122.001018_bib41","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1038\/jid.2011.167","article-title":"Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study","volume":"131","author":"Wahie","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1124\/dmd.122.001018_bib42","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/pharmaceutics12100919","article-title":"Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters","volume":"12","author":"Weiss","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1124\/dmd.122.001018_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003252","article-title":"COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology","volume":"17","author":"White","year":"2020","journal-title":"PLoS Med"},{"key":"10.1124\/dmd.122.001018_bib44","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/jps.24663","article-title":"Chloroquine and Hydroxychloroquine Are Novel Inhibitors of Human Organic Anion Transporting Polypeptide 1A2","volume":"105","author":"Xu","year":"2016","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.122.001018_bib45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/dmd.106.013359","article-title":"Misuse of the well-stirred model of hepatic drug clearance","volume":"35","author":"Yang","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001018_bib46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cpt.2236","article-title":"Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data","volume":"110","author":"Yee","year":"2021","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624009474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624009474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.122.001018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T13:02:17Z","timestamp":1740747737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624009474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0090955624009474"],"URL":"https:\/\/doi.org\/10.1124\/dmd.122.001018","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A in vitro","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.122.001018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The Author(s)","name":"copyright","label":"Copyright"}]}}